🔴 Tscan Therapeutics is trading 8.43% down in pre-market with no fresh company-specific catalyst

Tscan Therapeutics is trading at $0.61, down -8.43% in pre-market, with no fresh company-specific catalyst identified for September 2, 2026.

• The latest major update remains Tscan Therapeutics’ August 12, 2026, second-quarter results and corporate update.
• Nasdaq futures are down 0.37%, but broader sentiment does not clearly explain the sharper decline.
• The move may reflect low-liquidity trading or a delayed reaction; recheck later filings, analyst actions, or clinical updates.